A human variant is any inherited or acquired difference in human DNA that distinguishes one person or population from another. In clinical genetics, the term usually refers to a change in a gene or chromosome that can affect health, disease risk, or drug response. This explainer defines key types, clarifies how variants are classified, and describes how evidence is evaluated to inform diagnosis and care. It is designed as a practical reference for clinicians, researchers, and readers who want an enduring understanding of human variants.
Basic Concepts and Terminology
Variants arise from differences in the sequence of DNA building blocks, known as nucleotides (adenine, cytosine, guanine, thymine). When a variant is present in a fertilized egg, it is inherited and found in most or all cells of the body; when it arises in a specific cell during development or after birth, it may be restricted to certain tissues. Common terms include mutation, allele, polymorphism, and pathogenic or likely pathogenic variant. These terms help describe where a variant lies on the spectrum of benign to clinically significant.
Types of Human Variants
Variants can be described by scale, mechanism, and location. Scale ranges from tiny changes in one or a few nucleotides to large rearrangements affecting whole chromosomes. Mechanisms include substitutions, insertions, deletions, duplications, and copy number changes. Location can be in protein-coding regions, regulatory regions, or noncoding regions with important regulatory roles.
Coding, Noncoding, and Structural Variants
Coding variants occur in regions that are translated into protein and can change the resulting amino acid sequence. Noncoding variants can affect how, when, or where genes are turned on and off, even if they do not alter protein sequence directly. Structural variants include deletions, duplications, inversions, and translocations, sometimes involving large stretches of DNA visible under a microscope or detectable only with genomic technologies.
Somatic Versus Germline Variants
Germline variants are present in reproductive cells and therefore inherited and detectable in most cells of the body. Somatic variants arise in non-germline cells after conception and are not passed to offspring, but they can play important roles in cancer and other localized conditions. Tools such as tumor profiling identify somatic changes that may guide therapy.
Classification and Reporting Standards
To communicate consistently, genetics professionals use standardized systems such as the American College of Medical Genetics and Genomics (ACMG) variant classification framework. Variants are categorized primarily by evidence strength into benign, likely benign, variant of uncertain significance (VUS), likely pathogenic, and pathogenic. These categories incorporate population data, functional assays, segregation patterns in families, and computational prediction when available.
ACMG Variant Categories at a Glance
| ACMG Category | Interpretation | Typical Clinical Use |
|---|---|---|
| Benign | Not expected to cause disease | Routine reporting, exclusion of causality |
| Likely Benign | Unlikely to cause disease, but not fully characterized | Low-risk reporting, reclassification possible |
| Variant of Uncertain Significance (VUS) | Evidence is insufficient to classify | Avoid clinical decisions; research follow-up |
| Likely Pathogenic | Likely contributes to disease risk | Consider targeted screening, family evaluation |
| Pathogenic | Clearly associated with disease when present | Confirm diagnosis, guide management and cascade testing |
How Human Variants Are Evaluated
Classification depends on multiple lines of evidence. Population frequency data indicate whether a variant is common in the general population, with rare variants more likely to be clinically relevant under ACMMGuidelines. Functional studies, such as in vitro assays or model systems, can show whether a variant affects protein function. Segregation within families and computational prediction tools also contribute to the evidence base. Expert panels periodically review and update classifications as new data emerge.
Implications for Health and Care
Understanding whether a human variant is benign, uncertain, or pathogenic informs clinical decisions. Pathogenic or likely pathogenic findings in known disease genes can lead to enhanced screening, prevention strategies, or targeted therapies for the affected individual and at-risk relatives. Variants of uncertain significance are typically not used for clinical decisions, but may be reclassified over time as evidence accumulates. Benign or likely benign variants support reassurance and appropriate avoidance of unnecessary follow-up.
Practical Context and Examples
As an example, variants in the BRCA1 and BRCA2 genes include germline pathogenic changes that substantially raise lifetime risk of certain cancers, prompting surveillance or risk-reducing options. In pharmacogenomics, some coding variants alter drug metabolism and influence dosing or adverse effect risk. Population screening programs and research consortia continually refine our knowledge about which variants matter and in which contexts. These evolving insights highlight why categories and evidence can change, and why periodic review is important.